Gene Therapy Payment Models Could Be One Focus For 'Cures II'
Executive Summary
House Republicans are eager to keep working on legislation to permit innovative payment models for curative gene and cell therapies. Democrats, for now, are focused on other priorities.
You may also be interested in...
Medicare Part D Redesign Backed By House Republicans Retools Manufacturer Discount
Failed amendment offered by House Energy & Commerce Committee’s ranking Republican during markup of Speaker Nancy Pelosi’s drug pricing bill, the proposal is in line with biopharma’s position on manufacturer price concessions in Part D and suggests a road map for the kind of bill that might pass the Senate.
Value-Based Contracts: Medicaid Best Price Concerns Could Be Eased With CMS Guidance
Absent any legislative remedy, an administrative fix could provide manufacturers with confidence that value-based arrangements won’t trigger a new best price, Duke Margolis policy experts propose.
Cures 2.0: Can Congress Recapture The Legislative Magic?
Primary sponsors of the 21st Century Cures Act are trying to get the band back together. Is there hope to recapture a bipartisan, pro-innovation spirit in the current US Congress?